ArticleVeterinary and comparative oncology2012
Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.
Article in Veterinary and comparative oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Tyrosine kinase inhibitors as an alternative treatment in canine mast cell tumor.Frontiers in veterinary science · 2023Pooled it
- Preclinical/clinical trials of thrice-weekly administration of a combination of tegafur/gimeracil/oteracil (TS-1) and toceranib phosphate in dogs with intranasal tumors.The Journal of veterinary medical science · 2024Article
- A Scoping Review on Tyrosine Kinase Inhibitors in Cats: Current Evidence and Future Directions.Animals : an open access journal from MDPI · 2023Article
- Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.Cells · 2022Review
- Combination vinblastine and palladia for high-grade and metastatic mast cell tumors in dogs.The Canadian veterinary journal = La revue veterinaire canadienne · 2021Article
- Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms.Veterinary and comparative oncology · 2019Review
- A retrospective study of proteinuria in dogs receiving toceranib phosphate.The Canadian veterinary journal = La revue veterinaire canadienne · 2018Article
- Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs.Veterinary medicine and science · 2018Article
- A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies.BMC cancer · 2018Article
- A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma.BMC veterinary research · 2016Article
- Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.BMC veterinary research · 2016Article
- The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumours in vitro.Veterinary and comparative oncology · 2016Article
- Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.BMC veterinary research · 2015Article
- Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.BMC veterinary research · 2014Article
- Canine mast cell tumors: diagnosis, treatment, and prognosis.Veterinary medicine (Auckland, N.Z.) · 2014Review
- Phase 1 Dose-Escalation Study with LEC/chTNT-3 and Toceranib Phosphate (PalladiaJournal of cancer science & therapyArticle
- Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Combining drugs with known single-agent activity that lack overlapping dose-limiting toxicities (DLT) and exert antitumour activity through different mechanisms could improve clinical outcome. As toceranib and vinblastine meet these requisites, a phase I trial was performed in combination in dogs with mast cell tumours. The DLT for the simultaneous combination was neutropenia and the maximally tolerated dose was vinblastine (1.6 mg m(-2) every other week) concurrent with toceranib (3.25 mg kg(-1) PO, every other day). This represents greater than a 50% reduction in dose intensity for vinblastine (compared with single-agent use) and as such does not support this combination based on current drug combination paradigms. Although a strict adherence to dose paradigms speaks against the combination, evidence of significant activity (71% objective response) and enhanced myelosuppression suggest additive or synergistic activity. A prospective randomized evaluation comparing this combination with standard single-agent treatments would seem prudent to interrogate this potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.